This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barker, M. Articles by Eliason, J. Search for Related Content PubMed PubMed Citation Articles by Barker, M. Articles by Eliason, J.

Development of an Animal Brain Tumor Model and Its Response to Therapy with 1,3-Bis(2-chloroethyl)-1-nitrosourea¹

Howard C. Naffziger Laboratories for Neurosurgical Research, Department of Neurological Surgery, Cancer Research Institute [M. B., T. H., O. G., C. B. W., R. D., J. E.], and Department of Pathology [S. L. N.], University of California, San Francisco, California 94122

A chemically induced rat glioma, carried in cell culture, was transplanted to the brain of CDF rats. The tumor thrived in cell culture, producing a typical malignant astrocytoma when implanted in rat brain. Survival of tumor-bearing rats varied in different experimental groups, but the range of survival within each experimental group was within acceptable limits.

The rat glioma in cell culture grew progressively through three phases, namely, exponential, stationary, and a variable phase, limited by space and medium. The cell-cycle time of the glioma in vivo was 20 hr, the growth fraction was 0.35 to 0.46, the observed doubling time was 72 hr, and the cell-loss factor was 0.42. These data, along with the chronology of the cell-cycle phases, enhance the usefulness of this system as a model for brain tumor chemotherapy.

1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) significantly increased the survival time of rats bearing intracerebral gliomas. A dose of BCNU approximating 40% of the 10% lethal dose, when given 9 and 16 days after tumor implantation, produced an increased life-span of 38%. A dose of BCNU equivalent to 80% of the 10% lethal dose given on Days 9 and 16 produced an increased life-span of 84%. When BCNU was withheld until the 16th and 23rd days, a significant increase in survival time was still evident.

The advantages of this animal model for brain tumor chemotherapy are that (a) the transplanted tumor is of glial origin, (b) the tumor take of the model has been 100%, (c) the mean survival of animals is approximately 30 days, permitting the start of a treatment schedule after the tumor has grown to significant size, and (d) the rat is suitable for various routes of therapy.

¹ This work was supported in part by the American Cancer Society, California Division, by USPHS Clinical Cancer Research Center Grant 5 PO CA 11067, by NIH Cancer Center Grant CA 112 49-01, and by a gift from Phi Beta Psi Sorority.

² Present address: Department of Neurosurgery, University of Tokyo, Tokyo, Japan.

³ Present address: Department of Neurosurgery, Hacettepe University Medical Center, Ankara, Turkey.

⁴ Al Holman Undergraduate Fellow (1970 to 1971), United Commercial Benevolent Foundation, Inc.

⁵ Al Holman Undergraduate Fellow (1969 to 1970), United Commercial Benevolent Foundation, Inc.

Received 4/17/72. Accepted 1/26/73.

This article has been cited by other articles:

				S.-H. Kang, H. T. Cho, S. Devi, Z. Zhang, D. Escuin, Z. Liang, H. Mao, D. J. Brat, J. J. Olson, J. W. Simons, et al. Antitumor Effect of 2-Methoxyestradiol in a Rat Orthotopic Brain Tumor Model Cancer Res., December 15, 2006; 66(24): 11991 - 11997. [Abstract] [Full Text] [PDF]

				K. C. Lee, D. E. Hall, B. A. Hoff, B. A. Moffat, S. Sharma, T. L. Chenevert, C. R. Meyer, W. R. Leopold, T. D. Johnson, R. V. Mazurchuk, et al. Dynamic Imaging of Emerging Resistance during Cancer Therapy. Cancer Res., May 1, 2006; 66(9): 4687 - 4692. [Abstract] [Full Text] [PDF]

				N. S. Van Hoeven and A. D. Miller Improved Enzootic Nasal Tumor Virus Pseudotype Packaging Cell Lines Reveal Virus Entry Requirements in Addition to the Primary Receptor Hyal2 J. Virol., January 1, 2005; 79(1): 87 - 94. [Abstract] [Full Text] [PDF]

				N. Shinoura, Y. Yoshida, R. Tsunoda, M. Ohashi, W. Zhang, A. Asai, T. Kirino, and H. Hamada Highly Augmented Cytopathic Effect of a Fiber-mutant E1B-defective Adenovirus for Gene Therapy of Gliomas Cancer Res., July 1, 1999; 59(14): 3411 - 3416. [Abstract] [Full Text] [PDF]

				L. J. Yu, P. Drewes, K. Gustafsson, E. G. C. Brain, J. E. D. Hecht, and D. J. Waxman In Vivo Modulation of Alternative Pathways of P-450-Catalyzed Cyclophosphamide Metabolism: Impact on Pharmacokinetics and Antitumor Activity J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 928 - 937. [Abstract] [Full Text]

				B. D. Ross, Y.-J. Zhao, E. R. Neal, L. D. Stegman, M. Ercolani, O. Ben-Yoseph, and T. L. Chenevert Contributions of cell kill and posttreatment tumor growth rates to the repopulation of intracerebral 9L tumors after chemotherapy: An MRI study PNAS, June 9, 1998; 95(12): 7012 - 7017. [Abstract] [Full Text] [PDF]

				R. Brisman, E. M. Housepian, C. Chang, P. Duffy, and E. Balis Adjuvant Nitrosourea Therapy for Glioblastoma Arch Neurol, November 1, 1976; 33(11): 745 - 750. [Abstract] [PDF]

				V. A. Levin, M. Freeman-Dove, and H. D. Landahl Permeability Characteristics of Brain Adjacent to Tumors in Rats Arch Neurol, December 1, 1975; 32(12): 785 - 791. [Abstract] [PDF]